Evidence · fact check
Read past the healing claims.
Start with who was studied and what the study can answer. Then check the rules as a separate part of the decision.
Check who was studied
The study information below was last checked on September 28, 2026.
Animal healing
In a rat study, BPC-157 improved healing in a cut tendon.
That finding does not establish a healing benefit for people with tendon pain.
Ask whether a claim describes an animal experiment or a study in people.
Read the tendon study’s journal recordSmall human studies
The US Food and Drug Administration (FDA) counted five human studies, with about eighty people receiving BPC-157 in total.
Just two of those studies used a comparison between people who received BPC-157 and people who received a dummy treatment with no BPC-157.
As of September 28, 2026, those two studies had been described in short summaries for research meetings, but not detailed journal reports explaining how the studies were done and what they found.
A comparison group helps test whether a change comes from the treatment or from something else.
Read FDA’s account of the human studiesA trial still gathering answers
As of September 28, 2026, a hamstring-strain trial in China was recruiting and had no posted results.
A trial listing describes a plan and its status. It does not show that the treatment worked.
Open the government trial recordsWhat the pharmacy rules mean for your care
When a pharmacist or doctor mixes medicine for one particular patient, the process is called compounding.
A prescription does not settle the ingredient rules.
The federal rules in place as of September 26, 2026, bar BPC-157 as a raw ingredient for pharmacies making medicines for individual patients.
Note. Ask which law permits the pharmacy to make the proposed BPC-157 medicine, and request the rule in writing before booking or paying.
The request was about ingredients for pharmacy-made medicines.
FDA’s page, marked current April 22, 2026, says the requests to add BPC-157 to the raw-ingredient list for pharmacy-made medicines were taken back.
Note. A withdrawn request does not authorize a pharmacy to make BPC-157.
A committee vote does not change the rules.
As of September 28, 2026, FDA staff had advised against adding BPC-157 to that list of raw ingredients for pharmacy-made medicines. FDA had published no official vote record from its pharmacy advisory committee as of September 28, 2026. The committee is a group that gives FDA advice about pharmacy-made medicines.
Note. A committee vote gives only advice as of September 26, 2026; FDA must change the list using a process that includes a published draft rule and public comments.
As of September 26, 2026, larger facilities that make batches for clinics and hospitals follow a different part of federal compounding law.
If an offer involves one of those facilities, ask it to identify the law that permits the proposed BPC-157 medicine and provide the rule in writing. Do not assume that using a larger facility settles the question.
Read FDA’s withdrawn-request pageAsk what the claim leaves out
Look for the people studied, the comparison, and the limits. Ask whether the study matches your health problem. Keep a planned trial separate from a published result.
Compounded medicines lack approval from FDA; before sale, the agency does not assess manufacturing quality, how well the medicines work, or their safety (as of September 26, 2026).
A pharmacy’s involvement does not fill a gap in the evidence.
Read FDA’s explanation of compounding